| Patent Number |
Title Of Patent |
Date Issued |
| 6204300 |
Low resilience urethane foam |
March 20, 2001 |
| Low resilience urethane foam having excellent low resilience at room temperature and having capability of suppressing increase of hardness even at low temperature. The low resilience urethane foam, produced by reaction of urethane foam compositions comprising polyol (a), polyisocyanate ( |
| 6200958 |
Agent for treating high-risk impaired glucose tolerance |
March 13, 2001 |
| The present invention discloses an .alpha.-glucosidase inhibitor for prevention of transition from high-risk IGT to diabetes mellitus, for prophylaxis of diabetes mellitus, as well as for treating high-risk IGT. |
| 6197350 |
Method of producing a sustained-release preparation |
March 6, 2001 |
| A method of producing sustained-release microcapsules which comprises dispersing a physiologically active polypeptide into a solution of a biodegradable polymer and zinc oxide in an organic solvent, followed by removing the organic solvent; which provides a sustained-release preparat |
| 6194419 |
Nitrogen-containing heterocyclic compounds, their production and use |
February 27, 2001 |
| A compound of the formula: ##STR1##wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R.sup.1, R.sup.2 and R.sup.3 each is (i) H or (ii) a group bound via C, N, O or S; R.sup.4 is a group bound via C; R.sup.5 is H or a group bound via C or O; R.sup. |
| 6191107 |
Complex of human growth hormone and zinc |
February 20, 2001 |
| The present invention provides a complex of human growth hormone and zinc containing human growth hormone and zinc at a molar ratio of about 1:1.6 to about 1:2.4, and a sustained-release preparation which comprises the complex of human growth hormone and zinc and a biodegradable polymer |
| 6190702 |
Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase |
February 20, 2001 |
| A sustained-release preparation containing a bioactive polypeptide is prepared using a starting material containing a lyophilized product of an aqueous solution or suspension of the bioactive polypeptide in a non-ionic surfactant. The lyophilized product is dispersed in an oil phase, whi |
| 6190700 |
Production of sustained-release preparation for injection |
February 20, 2001 |
| Disclosed is a method of producing a sustained-release preparation for injection, which comprises adding to microspheres which are obtained from w/o emulsion with a solution containing a physiologically active peptide as an internal aqueous phase and a solution containing a polylactic ac |
| 6190695 |
Pharmaceutical composition containing osteogenesis-promoting substance |
February 20, 2001 |
| This invention provides a pharmaceutical composition comprising a non-peptide osteogenesis-promoting substance and a polyethylene glycol or a derivative thereof, which can be advantageously used as a agent for preventing or treating various bone diseases (e.g., osteoporosis) in view |
| 6187788 |
Condensed-ring thiophene derivatives, their production and use |
February 13, 2001 |
| A gonadotropin-releasing hormone antagonistic composition, which comprises an optionally substituted condensed-bicyclic compound consisting of a homo or hetero 5 to 7 membered ring and a homo or hetero 5 to 7 membered ring is effective as a propylactic or therapeutic agent for the preven |
| 6187340 |
Stabilized pharmaceutical preparation |
February 13, 2001 |
| A stabilized pharmaceutical preparation which is coated with a coating agent comprising an agent for the protection from light, said agent being capable of producing free radicals when exposed to ultraviolet rays, and a free radical scavenger; which is stable to light, especially ultravi |
| 6183971 |
Human betacellulin-specific antibodies and uses thereof |
February 6, 2001 |
| Disclosed are an antibody which have a binding activity to human betacellulin protein or a mutein thereof with specificity; especially a monoclonal antibody which does not have cross reactitivity with human epidermal growth factor (EGF) and human transforming growth factor a (TGF-.al |
| 6180792 |
Condensed-ring thiophene derivatives and thienopyrimide derivatives, their production and use |
January 30, 2001 |
| The thienopyrimidine derivatives of the present invention are described in the following formula: ##STR1##The thienopyrimidine derivatives of the present invention are useful for treating mammals suffering from disorders related to gonadotropin realeasing hormone (GnRH). |
| 6177587 |
Production method of aminobenzene compound |
January 23, 2001 |
| The present invention is to provide an industrially useful production method of an aminobenzene compound represented by the formula: ##STR1##which is characterized by reacting a mixture of a mono-halogeno compound represented by the formula: ##STR2##and di-halogeno compound represent |
| 6177452 |
Oxazole derivatives, their production and use |
January 23, 2001 |
| A novel compound of the formula: ##STR1##wherein R.sup.1 is a halogen atom, an optionally substituted heterocyclic, hydroxy, thiol or amino group; A is an optionally substituted acyl group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, or an o |
| 6177067 |
Hair revitalizing tonic composition containing a 2,2-dimethylpropanediol compound and use thereo |
January 23, 2001 |
| Disclosed is a hair revitalizing tonic composition containing a dimethylpropanediol derivative of the formula: ##STR1##wherein R.sup.1 and R.sup.2 are each independently a C.sub.1-30 hydrocarbon group which may be substituted, or a five- or six-membered heterocyclic group which conta |
| 6174904 |
Pharmaceutical composition |
January 16, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6174877 |
Carbapenem compound, their production and use |
January 16, 2001 |
| A cephem compound of the formula: ##STR1##wherein R.sup.1 stands for an optionally substituted lower alkyl group, R.sup.2 stands for H or a lower alkyl group, R.sup.3 stands for H, an optionally substituted hydrocarbon group, cyano group, a lower alkyloxy group or a lower alkylthio g |
| 6172090 |
Pharmaceutical composition |
January 9, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6172089 |
Pharmaceutical composition |
January 9, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6172085 |
Cyclic ether compounds as sodium channel modulators |
January 9, 2001 |
| A compound of the formula: ##STR1##wherein R.sup.1 and R.sup.2 each represents hydrogen, lower alkyl which may be substituted or acyl; R.sup.3, R.sup.4 and R.sup.5 each represents lower alkyl which may be substituted or lower alkoxy which may be substituted or R.sup.4 and R.sup.5 tak |
| 6172061 |
Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative |
January 9, 2001 |
| This invention is to provide a pharmaceutical composition for antagonizing CCR5 which comprises a compound of the formula: ##STR1##wherein R.sup.1 is an optionally substituted 5- to 6-membered ring; W is a divalent group of the formula: ##STR2##wherein the ring A is an optionally sub |
| 6169102 |
Oxazolone derivatives and their use as anti-Helicobacter pylori agent |
January 2, 2001 |
| An anti-Helicobacter pylori agent comprising a compound represented by the formula: ##STR1##wherein A represents an aromatic ring group which may be substituted; R.sup.1 and R.sup.2, whether identical or not, each represent a hydrogen atom or a hydrocarbon group which may be substitu |
| 6169100 |
Pharmaceutical composition |
January 2, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6169099 |
Pharmaceutical composition |
January 2, 2001 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6166215 |
Process for producing guanidine derivatives, intermediates therefor and their production |
December 26, 2000 |
| A process for producing the compound [I] or a salt thereof having excellent pesticidal activity as shown in the following schema. ##STR1## |
| 6166043 |
Pharmaceutical composition |
December 26, 2000 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6166042 |
Pharmaceutical composition |
December 26, 2000 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6166006 |
Anilide derivative, production and use thereof |
December 26, 2000 |
| This invention is to provide a compound of the formula: ##STR1## wherein R.sup.1 is an optionally substituted 5- to 6-membered ring: C is a divalent group of the formula: ##STR2## wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optional |
| 6162828 |
Cysteine protease inhibitor |
December 19, 2000 |
| A pharmaceutical composition for inhibiting cysteine protease which comprises a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an acyl group; R.sup.2, R.sup.3 and R.sup.4, same or different, are a bond, an amino acid residue or a group of the formula:in w |
| 6160126 |
Synthetic Intermediates for the preparation of N, N'-Di-substituted isothiourea derivatives and |
December 12, 2000 |
| Novel Intermediates ##STR1## wherein R is a substituted or unsubstituted hydrocarbon residue or acyl group; X is an electron withdrawing group; Y.sup.1 and Y.sup.2, which are the same or different, are each independently oxygen or sulfur; and A is a substituted or unsubstituted, |
| 6156773 |
Pharmaceutical composition |
December 5, 2000 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6150384 |
Pharmaceutical composition |
November 21, 2000 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6150383 |
Pharmaceutical composition |
November 21, 2000 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6147071 |
Cyclic compounds, their production and use |
November 14, 2000 |
| Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.CC<, --CO--N< or --CS--N< as the partial structure --X . . . . . Y<; R.sup.a and R.sup.b are bonded to each other to form Ring A, or they are t |
| 6147051 |
Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction |
November 14, 2000 |
| Compounds having antagonistic activity on endothelin receptors can be effectively used for prophylaxis and/or treatment of hypofunction of organs which occurs in their surgery or transplant. |
| 6140325 |
Thienopyrimidine derivatives, their production and use |
October 31, 2000 |
| Thienopyrimidine derivatives are disclosed. Also disclosed are methods for the production and use of these compounds. |
| 6136781 |
LH-RH receptor antagonists |
October 24, 2000 |
| The LH-RH receptor antagonists containing cyclic pentapeptides or salts thereof and novel cyclic pentapeptide or salts thereof are provided.The LH-RH receptor antagonists of the present invention are effective as medicines for preventing and curing sex hormone-dependent cancers (e.g., pr |
| 6133502 |
Monocyte chemoattractant protein and its receptor transgenic animal |
October 17, 2000 |
| Provided is a non-human animal in which an exogeneous gene, a mutant gene thereof of a monocyte chemoattractant protein and/or a receptor thereof is introduced. The present transgenic animals can be utilized as a pathologic model animal for heart diseases, respiratory diseases, joint dis |
| 6133295 |
Pharmaceutical composition |
October 17, 2000 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6133293 |
Pharmaceutical composition |
October 17, 2000 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6133278 |
Use of quinone and hydroquinone derivatives for the treatment of cachexia |
October 17, 2000 |
| A pharmaceutical composition for treating cachexia which containing a compound (I) ##STR1## wherein R.sup.1, R.sup.2 is H, alkyl, alkoxy, may form --CH.dbd.CH--CH.dbd.CH--; R.sup.3 is H, alkyl; R.sup.4 is N-containing heterocyclic; R.sup.5 is H, alkyl, hydroxyalkyl, carboxyl; Z i |
| 6132988 |
DNA encoding a neuronal cell-specific receptor protein |
October 17, 2000 |
| To provide a method of isolating and detecting a new receptor gene, as a means of elucidating the function of neuronal cell-specific receptors, especially of elucidating the detailed mechanism of the neuronal cell differentiation inhibitory and nerve nutrition factor-like actions of |
| 6124297 |
.alpha.-unsaturated amines, their production and use |
September 26, 2000 |
| .alpha.-Unsaturated amines of the formula: ##STR1## wherein X.sup.1 and X.sup.2 are such that one is an electron-attracting group with the other being a hydrogen atom or an electron-attracting group; R.sup.1 is a group attached through a nitrogen atom; R.sup.2 is a hydrogen atom |
| 6124243 |
Method of controlling graminaceous weeds |
September 26, 2000 |
| A herbicide comprising the sulfonylurea derivatives of the formula (I): ##STR1## wherein Q is --CH.dbd.CH-- or --S--, R is C.sub.1-3 alkyl, and X is --OCH.sub.3 or --CH.sub.3 ; or a salt thereof, are useful for the control of undesired vegetation, for example, black glass (Alopecurus |
| 6121295 |
Pharmaceutical composition |
September 19, 2000 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6121294 |
Pharmaceutical composition |
September 19, 2000 |
| Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabe |
| 6121057 |
Methods of detecting antibodies to .alpha.-Fodrin and fragments thereof in diagnosing sjogrens' |
September 19, 2000 |
| Screening of the autoantibodies and autoantigens which are specific to Sjogren's syndrome, particularly primary Sjogren's syndrome, and provision of a prophylactic and therapeutic drug for Sjogren's syndrome, particularly primary Sjogren's syndrome, and a highly sensitive diagnostic |
| 6117645 |
Human LH-RH receptor expression cells and use thereof |
September 12, 2000 |
| Disclosed are CHO cells which are capable of continued production of human LH-RH receptor proteins, or cell membrane fractions thereof; recombinant human LH-RH receptor proteins or partial peptides thereof; methods for screening compounds which have affinity for an LH-RH receptor by |
| 6117455 |
Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
September 12, 2000 |
| A sustained-release microcapsule contains an amorphous water-soluble pharmaceutical agent having a particle size of from 1 nm-10 .mu.m and a polymer. The microcapsule is produced by dispersing, in an aqueous phase, a dispersion of from 0.001-90% (w/w) of an amorphous water-soluble ph |
| 6114139 |
G-protein coupled receptor protein and a DNA encoding the receptor |
September 5, 2000 |
| DNA primers effective in screening G protein coupled receptor protein-encoding DNA fragments are provided. The primers which are complementary to nucleotide sequences that are in community with (homologous to) the nucleotide sequences encoding amino acid sequences corresponding to or |
